| Objective:The purpose of this research was to study the expression and clinical significance of serum ROS and sVCAM-1in patients with sudden sensorineural hearing loss.Methods:Serum ROS and sVCAM-1levels were detected by enzyme-linked immunosorbent assay (ELISA) in31patients with sudden sensorineural hearing loss and31normal persons. The correlations between ROS, sVCAM-1levels and the patients’ gender, age, smoking, upper respiratory tract infection, the degree of hearing loss and the effection of treatment were studied.Results:1. ROS and sVCAM-1levels were significantly higher in patients with sudden sensorineural hearing loss, the difference was statistically significant (p<0.01).2. A positive association was observed between the expressions of ROS and sVCAM-1in patients with sudden sensorineural hearing loss (p<0.05).3. ROS and sVCAM-1levels in patients under40years old were significantly higher than patients older than40years, the difference was statistically significant (p<0.05).4. Compared with the non-smoking population, ROS and sVCAM-1levels in smoking patients were significantly higer, the difference was statistically significant (p<0.05). 5. ROS, sVCAM-1levels in patients with respiratory tract infection were significantly higher than patients without respiratory tract infection, the difference was statistically significant (p<0.05).6. ROS, sVCAM-1levels in patients with effective treatment was significantly higher than patients without effective treatment, the difference was statistically significant (p<0.05).7. ROS, sVCAM-1levels were not correlated with gender and the degree of deafness in patients with sudden sensorineural hearing loss.Conclusion:1. Increased serum ROS and sVCAM-1levels may play a crucial role in the pathogenesis of sudden sensorineural hearing loss.2. ROS, sVCAM-1levels were correlated with age, smoking and upper respiratory tract infection in patients with sudden sensorineural hearing loss, however, they were not correlated with gender and the degree of deafness. |